CenTrial Logo

Immunosuppression improves Lung Function in Patients with RA-associated ILD

by


Immunosuppression improves lung function with rheumatoid arthritis associated interstitial lung disease

Rheumatoid Arthritis (RA) is characterized by chronic inflammation of the joints, leading to pain, stiffness, and swelling. This autoimmune disease primarily affects the joints. However, it can also affect other organs, including the lungs. Rheumatoid arthritis-associated interstitial lung disease (ILD) is a condition where inflammation and scarring occur in the lung tissue as a complication of rheumatoid arthritis.

In RA-associated ILD, inflammation and scarring occur in the interstitial space of the lungs, leading to the thickening and stiffening of the lung tissue. This can impair the lung's ability to expand and contract properly. RA-associated ILD may be diagnosed through imaging studies such as chest X-rays, CT scans, and pulmonary function tests which assess lung function. Symptoms of RA-associated ILD may include shortness of breath, cough, chest pain, fatigue, and unexplained weight loss. However, symptoms can vary widely depending on the severity and extent of lung involvement.

Treatment for RA-associated ILD typically involves managing the underlying rheumatoid arthritis and addressing the lung inflammation and scarring. This may include corticosteroids and other immunosuppressive drugs to reduce inflammation, oxygen therapy to improve breathing, and pulmonary rehabilitation to help maintain lung function.

Clinical Trial

To investigate the impact of immunosuppression on lung function in patients with RA-associated ILD, researchers conducted a retrospective study using data from five ILD centers. They identified 212 patients with RA who received treatment with mycophenolate, azathioprine, or rituximab and analyzed changes in lung function before and after treatment using statistical models.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me

Findings

The results showed that after 12 months of treatment, there was an improvement in forced vital capacity, which is a measure of lung function, compared to the expected trajectory without treatment. Diffusing capacity of the lungs for carbon monoxide, another measure of lung function, also improved after 12 months of treatment. The choice of immunosuppressive agent or the radiologic pattern of ILD did not significantly impact the lung function trajectory on immunosuppression.

Conclusion

The researchers concluded that immunosuppression was associated with improved lung function in patients with RA-associated ILD. However, they emphasized the need for prospective, randomized trials to validate these findings and provide more substantial evidence for using immunosuppression to treat this condition.

Early diagnosis and management of RA-associated ILD are essential to prevent further lung damage and improve outcomes. Regular monitoring and close collaboration between rheumatologists and pulmonologists are often necessary for the optimal management of this condition.
__________



Share this article with a friend:
     


Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.


This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.